Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | BTK C481Y |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
BTK C481Y | diffuse large B-cell lymphoma | resistant | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, diffuse large B-cell lymphoma cell lines expressing BTK C481Y demonstrated resistance to Imbruvica (ibrutinib) in culture (PMID: 36183831). | 36183831 | |
BTK C481Y | hematologic cancer | resistant | Acalabrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing BTK C481Y were resistant to treatment with Calquence (acalabrutinib) in culture (PMID: 35639855). | 35639855 | |
BTK C481Y | hematologic cancer | resistant | Zanubrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing BTK C481Y were resistant to treatment with Brukinsa (zanubrutinib) in culture (PMID: 35639855). | 35639855 | |
BTK C481Y | hematologic cancer | sensitive | A-419259 | Preclinical - Cell culture | Actionable | In a preclinical study, A-419259 inhibited colony formation in an Imbruvica (ibrutinib)-resistant cell line harboring BTK C481Y in culture (PMID: 35639855). | 35639855 | |
BTK C481Y | lymphoma | predicted - sensitive | DZD8586 | Preclinical - Cell culture | Actionable | In a preclinical study, DZD8586 inhibited proliferation of lymphoma cells expressing BTK C481Y in culture (Blood (2023) 142 (Supplement 1): 2822). | detail... |